ATAI Beckley (ATAI) said Thursday it that the US Patent and Trademark Office has granted a new patent covering EMP-01, which is intended to treat social anxiety disorder.
The patent includes claims to the drug substance of EMP-01 and is expected to provide exclusivity through 2043. It also protects critical drug substance attributes of the drug candidate.
Shares of the company rose more than 2% in recent premarket activity Thursday.
Price: 4.43, Change: +0.10, Percent Change: +2.31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments